首页 > 市场调查报告书 > 製药

自体免疫疾病

市场调查报告书

商品编码

1122413

纤维肌痛治疗市场：按药物类别（抗抑郁药、抗癫痫药、肌肉鬆弛剂、镇痛药等）、按分销渠道、按地区分类 - 2022-2030 年的规模、份额、前景、机会分析

Fibromyalgia Treatment Market, by Drug Class (Antidepressants, Antiepileptics, Muscle Relaxants, Analgesics, and Others ), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月16日 | 出版商:

Coherent Market Insights | 英文 176 Pages | 商品交期: 2-3个工作天内

价格

简介目录

纤维肌痛是一种常见且复杂的慢性疼痛疾病，可导致肌肉骨骼疼痛、疲劳和局部压痛，并带来心理、身体和社会后果。纤维肌痛主要是由遗传条件引起的，但确切原因尚不清楚。纤维肌痛最常见的症状是疲劳、睡眠困难、慢性肌肉疼痛和压痛点。其他症状包括头痛、肌肉酸痛、烧灼感、痉挛、紧绷感、注意力不集中、疲劳和抑郁。纤维肌痛症状可能会随着时间的推移而累积，并且可能是由多种外部因素引起的。纤维肌痛的治疗包括治疗、药物、有规律的有氧运动和减压。此外，纤维肌痛治疗开出抗抑郁药和止痛药来治疗抑郁、焦虑、疼痛和疲劳。FM/a 测试是用于诊断纤维肌痛的血液测试。无论年龄大小，它都可以用于至少有四种典型纤维肌痛症状的患者。有三种专门批准用于纤维肌痛的药物：度洛西汀（Cymbalta）、米那普崙（Sabella）和普瑞巴林（Lyrica）。非处方止痛药用于治疗纤维肌痛。像阿片类药物这样的强效药物不是长期使用的，而且会让人上瘾。

市场动态

市场上的主要参与者正专注于开发治疗纤维肌痛的新型药物的研发活动。在纤维肌痛治疗市场推出新药预计将在预测期内推动纤维肌痛治疗市场的增长。

例如，2018 年 12 月，Aptinyx Inc., Biotech Company宣布了对 NYX-2925 的探索性研究的中期分析的积极结果，NYX-2925 是一种新型 NMDA 受体 (NMDAr) 调节剂，用于纤维肌痛患者。研究中的受试者接受两种剂量水平的 NYX-2925、20mg 和 200mg，以及每天口服安慰剂，持续六週。

2017 年，Virios Therapeutics, Biotechnology company宣布，《Journal of Pain Research》公布了 IMC-1 治疗纤维肌痛的 2 期 PRID-201 试验的关键顶线结果。这项为期 16 週的随机、双盲、安慰剂对照试验在 12 个美国研究中心进行，招募了 143 名 ACR2010 标准定义的纤维肌痛患者。在 PRID-201 试验中，随机分配至 IMC-1（celecoxib+famciclovir）的患者与随机分配至安慰剂的患者相比，纤维肌痛相关疼痛明显减轻。

此外，过去几年，Sun Pharmaceutical Industries、Mylan NV 和 Teva Pharmaceuticals Industries 等主要仿製药製造商推出了治疗纤维肌痛的仿製药。

此外，2021 年 9 月，阿拉巴马大学伯明翰分校进行了一项研究，以评估右美沙芬 (DXM) 是否能减轻纤维肌痛 (FM) 的疼痛。右美沙芬 (DXM) 是一种在一些非处方产品中发现的药物，包括止咳药。这种药物可以通过抑制中枢神经系统的炎症来减轻纤维肌痛 (FM) 的疼痛。右美沙芬（DXM）仍处于第二阶段试验。

本次调查的主要特点

本报告对全球纤维肌痛治疗市场进行了深入分析，展示了以 2021 年为基准年的预测期间（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。
它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资主张矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景和主要参与者采用的竞争战略的关键见解。
根据公司亮点、产品组合、关键亮点、财务业绩和战略等参数对全球纤维肌痛治疗市场的主要参与者进行了分析。
本研究涉及的主要公司包括Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
本报告中的见解将使营销人员和公司管理层能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
全球纤维肌痛治疗市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以通过用于分析全球纤维肌痛治疗市场的各种战略矩阵来促进他们的决策。

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue, and localized tenderness affecting individuals mentally, physically, and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain, and tender points. An individual with fibromyalgia can also have symptoms such as headaches, muscle pain, burning, twitching, or tightness, poor concentration, draining fatigue and depression. Fibromyalgia symptoms might accumulate with time or it can be caused by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for the treatment of fibromyalgia, antidepressants or pain medications are prescribed to treat depression, anxiety, pain, and fatigue. The FM/a Test is a blood test used for the diagnosis of fibromyalgia. It is available for use in patients of any age who have at least four of the typical symptoms of fibromyalgia. The three drugs approved specifically for fibro pain are Duloxetine (Cymbalta), Milnacipran (Savella), Pregabalin (Lyrica). Over-the-counter painkillers are used in treating fibromyalgia. Stronger medicines, like opioids,are not prescribed for long term use, and you could become dependent on them.

Market Dynamics

Key players in the market are focusing on research and development activities for the development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period.

For instance, in December 2018, Aptinyx Inc., Biotech Company announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

In 2017, Virios Therapeutics, Biotechnology company announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.

Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. launched generic drugs for fibromyalgia treatment in the market.

Furthermore, in September 2021, University of Alabama at Birmingham, carried out a study to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. Dextromethorphan (DXM) is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce Fibromyalgia (FM) pain by suppressing inflammation in the central nervous system. The Dextromethorphan (DXM) is still in phase 2 trial.

Key features of the study:

This report provides an in-depth analysis of the global fibromyalgia treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global fibromyalgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibromyalgia treatment market

Detailed Segmentation:

Global Fibromyalgia Treatment Market, By Drug Class:
- Antidepressants
  - Milnacipran (Savella and Other Generics)
  - Duloxetine (Cymbalta and Other Generics)
  - Others
- Antiepileptics
  - Pregabalin (Lyrica and Other Generics)
  - Others
- Muscle Relaxants
- Analgesics
- Others (Including Pipeline Drugs)
Global Fibromyalgia Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Fibromyalgia Treatment Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- Eli Lilly and Company*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer, Inc.
- Novartis AG
- Allergan plc.
- Sun Pharmaceutical Industries Ltd.
- Aptinyx, Inc.
- Prismic Pharmaceuticals, Inc.
- Innovative Med Concepts, Inc.
- Intec Pharma Ltd.
- Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Pipeline Analysis
Patent Litigations
Reimbursement
Patent Landscape (ANDA/NDA Intelligence)
PEST Analysis
Porter's Analysis

4. Global Fibromyalgia Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the market

5. Global Fibromyalgia Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Antidepressants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Segment Trends
Milnacipran (Savella and Other Generics)
Duloxetine (Cymbalta and Other Generics)
Others
Antiepileptics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Segment Trends
Pregabalin (Lyrica and Other Generics)
Others
Muscle Relaxants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Analgesics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Others (Including Pipeline Drugs)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Fibromyalgia Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Fibromyalgia Treatment Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
- Pfizer, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Novartis AG
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Allergan plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Sun Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Aptinyx, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Prismic Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Innovative Med Concepts, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Intec Pharma Ltd
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies
- Astellas Pharma Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Market Strategies

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

纤维肌痛治疗市场：按药物类别（抗抑郁药、抗癫痫药、肌肉鬆弛剂、镇痛药等）、按分销渠道、按地区分类 - 2022-2030 年的规模、份额、前景、机会分析